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Abstract
Computational ligand docking methodology, AutoDock 4.0, based on Lamarckian genetic algorithm was employed for virtual screening of a 
compound  library  with  13  entries  including  reference  compound  as  fluconazole  with  the  enzyme  Cytochrome  P-450-14-Alpha-Sterol 
Demethylase (Cyp51), a potential antifungal drug target. Considering free energy of binding as a criteria of evaluation, a total of 12 compounds 
were predicted to be potential inhibitors of Cytochrome P-450-14-Alpha-Sterol Demethylase (Cyp51) and 10 compounds displayed greater 
binding affinities than fluconazole as Cytochrome P-450-14-Alpha-Sterol Demethylase (Cyp51) Inhibitor. Compound 1a & 1b were the most 
potent in inhibiting the Cytochrome P-450-14-Alpha-Sterol Demethylase (Cyp51), in silico. Putative interactions between Cytochrome P-450-14-
Alpha-Sterol Demethylase (Cyp51) and inhibitors were identified by inspection of docking-predicted poses. This understanding of protein–ligand 
interaction and value of binding energy imparts impetus to the rapid development of novel Cytochrome P-450-14-Alpha-Sterol Demethylase 
(Cyp51). 
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Introduction
Azole antifungal agents are useful drugs and are widely used for the 
treatment of topic or inner mycoses, in particular AIDS-related   
1-4 mycotic pathologies.  It is well-known that azole derivatives block 
ergosterol biosynthesis, causing its depletion and accumulation of 
5-7 lanosterol and some other 14-methylsterols.  Such sterols alter 
membrane fluidity with concomitant reduction in the activity of 
membrane-associated  enzymes,  increased  permeability,  and 
8-9 inhibition of cell growth and replication.  The intermediate step of 
ergosterol  biosynthesis  is  the  demethylation  of  lanosterol 
performed by 14-á-lanosterol demethylase (P-450-14 , CYP51), a  DM
member  of  the  enzyme  cytochrome  P-450  dependent 
10,11 superfamily,  which catalyzes the removal of 14- á -methyl group 
of lanosterol. Crossover inhibition of CYP51 in different species is 
assumed to cause undesirable side effects and is one of the reasons 
for the search of better, more selective agents.
The problem of specificity is commonly addressed empirically by 
applying computer simulation techniques such as receptor fitting 
and receptor mapping. In the first approach, the development of 
structural models for the active site of enzymes (based on primary 
sequence analyses and modeling by homology) is exploited. The 
structures of a number of P-450-dependent enzymes belonging to 
prokaryotic  microorganisms,  such  as  P-450cam  from 
12 Pseudomonas  putida,   P450eryF  from  Saccaropolyspora   
13 14 erythrea,   and  P-450ter  from  Pseudomonas  sp.,   have  been 
elucidated,  while  only  the  crystal  structure  of  a  CYP51 
cytochrome,  a  soluble  orthologue  from  Mycobacterium 
15 tuberculosis (MTCYP51), is available until now.  Despite a limited 
sequence  identity  (generally  10-30%),  all  cytochromes  P-450 
show  very  similar  secondary  and  tertiary  structures; 
consequently, homology modeling studies have been performed in 
the  past  few  years,  starting  from  3D  structures  of  the 
16-18 abovementioned prokaryotic enzymes.
Docking-based drug design by use of structural biology remains 
one of the most rational approaches in drug discovery process. 
The structured knowledge of the binding capabilities of the active 
site residues to specific groups on the agonist or antagonist leads 
to proposals for synthesis of very specific agents with a high 
19 probability of biological action.  Two of the most commonly used 
methodologies  in  structure-based  CADD  are  docking  and 
20 molecular mechanics.
Molecular  docking  is  a  very  popular  method  introduced  to 
investigate molecular association and is particularly useful in the 
drug  discovery  field  to  study  the  binding  of  small  molecules 
21 (ligands) to macromolecules (receptor).  This involves two key 
components, namely the search algorithm and scoring function; 
former positions the molecules in orientations and conformations 47                                                                    Journal of PharmaSciTech
within  the  active  sites,  while  latter  one  determining  if  the 
orientation  chosen  by  search  algorithm  is  most  energetically 
22  favorable. A  rigorous  search  algorithm  would  exhaustively 
elucidate all possible binding modes between ligand and receptor. 
The essence of GA is the evolution of a population of possible 
solution  via  genetic  operators  to  final  population,  optimizing  a 
23 predefined fitness function.  Autodock 4.0 uses GA as a global 
optimizer combined with energy minimization as a local search 
24 method.
The nonbonded oxygen atoms of waters, present in the crystal 
structure were removed. After assigning the bond orders, missing 
hydrogen atoms were added, then the partial atomic charges was 
calculated using Gasteiger–Marsili method (Gasteiger). United 
atom charges were assigned, non-polar hydrogens were merged, 
and rotatable bonds were assigned, considering all the amide 
bonds as non-rotatable. The receptor file was converted to pdbqt 
format, which is pdb plus ''q'' charges and ''t'' AutoDock type. (To 
confirm the AutoDock types, polar hydrogens should be present, 
whereas non-polar hydrogens and lone pair should be merged, 
each atom should be assigned Gasteiger partial charges).
Molecular docking studies
Prior to actual docking run, AutoGrid 4.0 was introduced to pre-
calculate grid maps of interaction energies of various atom types. 
In all dockings, a grid map with 100*100*100 points, a grid 
spacing  of  0.675  A°  (roughly  a  half  of  the  length  of  a 
carbon–carbon  single  bond)  were  used,  and  the  maps  were 
Materials and methods
Materials
The  macromolecule,  Cytochrome  P-450  14-Alpha-Sterol 
Demethylase (Cyp51) model was built by using AutoDock Tools-
1.4.6  and  MGL  Tools-1.5.4  packages  (The  Scripps  Research 
Institute, Molecular Graphics Laboratory, 10550 North Torrey Pines 
Road, CA, 92037) running on LINUX, (FEDORA-2008)
Ligand receptor modeling
Acd/3d viewer Version 8.0 for microsoft windows was used to draw 
the 2D structures of different ligands. Ligands were further refined 
and cleaned in 3D by addition of explicit hydrogens and gradient 
optimization  function  of  Prodrg  server.  All  the  structures  were 
written  in  pdb  format.  Input  molecules  files  for  an  AutoDock 
experiments must confirm to the set of atom types supported by it. 
AutoDock requires that ligands got partial atomic charges and 
AutoDock atom types for each atom; it also requires a description of 
the rotatable bond in the ligand. This set consists of united atom 
aliphatic carbons, aromatic carbons in cycles, polar hydrogens, 
hydrogen-bonded nitrogen, and directly hydrogen-bonded oxygen 
among others, each with partial charges. Therefore, pdbqt format 
was used to write ligands, recognized by AutoDock.
Torsional degree of freedom (TORSDOF) is used in calculating the 
change in the free energy caused by the loss of torsional degree of 
freedom upon binding. In the AutoDock 4.0 force field, the TORSDOF 
value for a ligand is the total number of rotatable bonds in the ligand. 
This number excludes bonds in rings, bonds to leaf atoms, amide 
bonds, and guanidinium bonds.
It  consists  of  several  steps.  First,  the  3D  crystal  structure  of 
Cytochrome P-450-14-Alpha-Sterol Demethylase (Cyp51) (Fig. 1); 
PDB entry 1H5Z was downloaded from Brookhaven protein data 
bank (PDB; http://www.rcsb.org/pdb), and subsequently sequence 
identity was determined by following the process provided in the 
website as follows. http://blast.ncbi.nlm.nih.gov/Blast.cgi.   As a 
result of the search more than 30% similarity was noticed, therefore 
homology modeling was not performed with the enzyme under 
study. The details of the percent similarity has been shown in the 
following Table 1 and loaded to python molecular viewer.
Fig.1: Native structure of Cytochrome P-450-14-Alpha-Sterol 
Demethylase (Cyp51) (PDB ID: 1H5Z)
Table 1: Sequence alignment output of Cytochrome P-450-14-
Alpha-Sterol Demethylase (Cyp51)
Accession
NP_000777.1
NP_001139624.1
Description
lanosterol 
14-alpha 
demethylase 
isoform 1 
precursor 
[Homo 
sapiens]
Max 
score
Total 
score
Query 
coverage
E 
value
Max 
identity 
243 243 95% 3e-77 33%
lanosterol 
14-alpha 
demethylase 
isoform 2 
[Homo 
sapiens]
230 230 89% 3e-73 34%48                                                           Journal of PharmaSciTech
 algorithm (LGA) based on the optimization algorithm  was used, 
since  preliminary  experiments  using  other  two  (Simulated 
annealing  and  genetic  algorithm)  showed  that  they  are  less 
efficient, utilizes Lamarckian notation that an adaptations of an 
individual to its environment can be inherited by its offspring. For 
all dockings, 40 independent runs with step sizes of 0.2Å for 
translations  and  5Å  for  orientations  and  torsions,  an  initial 
population of random individuals with a population size of 150 
individuals, a maximum number of 2500000 energy evaluations, 
maximum number of generations of 27,000, an elitism value of 1, 
and a number of active torsion of 8 were used. AutoDock Tools 
along with AutoDock 4.0 and AutoGrid 4.0 was used to generate 
both  grid  and  docking  parameter  files  (i.e.,  gpf  and.dpf  files) 
respectively.
N
N
N
R
1
R
2
R
3
(1)
Table 2: Docking output of compounds 1(a-l) and reference compound, fluconazole
SH
NH OH
O H
Cmpnd (1)
1 R
2 R
3 R
Free energy of binding
(Kcal/mole)
Surrounding residue
-NH2 O2N -8.59 PRO 215
SH
NH OH
O H
-CH3
 
Cl
-8.26 GLN 374,
LEU 378.
a.
b.
SH
NH
O H
c.
 
-8.15
PRO 422,
ARG 443.
SH
NH OH
O H NO 2
NH 2
O2N -8.02 LYS154 d.
SH -7.91 LYS 232,
GLU 234.
e.
f. SH OH 7.73
PHE 88,LEU 99,
GLU 97, MET 248.
N N
O
S H SO2NH2
O2N -7.62
ASP 161,GLY 162,
GLU 141,ARG 163.
g.
SH
NH OH
O H
NO2
O2N -7.56
GLU 141, GLY 162,
ARG 163, ASP 161. h.
-NH2
-NH2
-NH2
-NH2
centered on the ligand binding site. In an AutoGrid procedure, the 
protein is embedded in a 3D grid and a probe atom is placed at each 
grid point. The energy of interaction of this single atom with the 
protein is assigned to the grid point. An affinity grid is calculated for 
each type of atoms in the substrate, typically carbon, oxygen, 
nitrogen, and hydrogens as well as grid of electrostatic potential 
using a point charge of 1 as the probe. Autodock 4.0 uses these 
interaction  maps  to  generate  ensemble  of  low  energy 
conformations. It uses a scoring function based on AMBER force 
field, and estimates the free energy of binding of a ligand to its 
target. For each ligand atom types, the interaction energy between 
the ligand atom and the receptor is calculated for the entire binding 
site which is discretized through a grid. This has the advantage that 
interaction energies do not have to be calculated at each step of the 
docking process but only looked up in the respective grid maps. 
Since a grid map represents the interaction energy as a function of 
the coordinates, their visual inspection may reveal the potential 
unsaturated hydrogen acceptors or donors or unfavorable overlaps 
between the ligand and the receptor. Of the three different search 
algorithms offered by AutoDock 4.0, the Lamarckian Genetic 49                                                           Journal of PharmaSciTech
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S H
O H
Cl NH2
-7.28 GLU 35, PRO 6,
ARG 7. j.
k.
S H
O H
Cl
-CH3 -6.96
GLY 329, PHE 331,
ASP 68, LYS 323,
GLU 330, LYS 328.
S H
O H
Cl
-CH -CH 2 3 -5.98 LEU 185, ASP 182,
TYR 184. l.
NH2
NH2
Fig.2: Molecular surface view of compound 1a docked within 
the binding pocket of the enzyme 1H5Z
Fig.3: Molecular surface view of compound 1b docked in the 
binding pocket of the enzyme1H5Z
Fig.4: Molecular surface view of reference compound, 
fluconazole docked in the binding pocket of the enzyme 1H5Z
The results of LGA docking experiments of the Polysubstituted 
Triazoles using AutoDock 4.0 and AutoGrid 4.0 are summarized in 
Table 2. For each docking experiment, the lowest energy docked 
conformation  was  selected  from  40  runs.  The  successful 
completion of docking experiment took 2 hours, on a 2.0 GHz Intel 
(R) core 2 duo machine with 3.0 GB of RAM and LINUX (FEDORA-
2008) operating system.
In order to evaluate accuracy of docking, binding energy and 
numbers  in  cluster  was  used.  10  molecules  showed  better 
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inhibition  potential  than  fluconazole  as  Cytochrome  P-450-14-
Alpha-Sterol Demethylase (Cyp51) Inhibitor with binding energy -
7.04 kcal/mole. The chemical structures of all the 13 molecules 
including the reference are shown in the Table 2.  Modeling and 
docking analysis revealed the nature of the active site and some key 
interactions that enabled the binding of Cytochrome P-450-14-
Alpha-Sterol  Demethylase  (Cyp51)  Inhibitor  to  the  active  site. 
Among all molecules (12) screened, the docking interactions of 
compound 1 with  PRO 215 appeared to be in close proximity and 
explains the high Cytochrome P-450-14-Alpha-Sterol Demethylase 
(Cyp51)  selectivity  observed.  Docking  poses  and  binding 
interactions of   and the first two highest binding energy compound 
(1, 2) and fluconazole are shown in Fig. 2-4. 
This study contributes molecular insight into the binding process, 
which is of great pivotal importance for designing new ligands 
interfering with Cytochrome P-450-14-Alpha-Sterol Demethylase 
(Cyp51)  and  shows  that  new  wave  of  flexible  ligand  docking 
program  like  Auto    dock  can  produce  unbiased  docking  of 
Cytochrome  P-450-14-Alpha-Sterol  Demethylase  (Cyp51) 
inhibitors  in  the  enzyme  active  site.    The  binding  interactions 
revealed from docking poses provide the clues for the design of new 
molecules  thus  giving  insight  on  structural  requirement  for 
designing more potent analogs.
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